SAN DIEGO, June 25, 2014 /PRNewswire/ -- Bloomberg BNA and law firm Robins, Kaplan, Miller, & Ciresi L.L.P, in conjunction with the Biotechnology Industry Organization, today published a study on the impact of recent U.S. Supreme Court decisions affecting the life sciences industry. The report, Stopped at the Threshold: The Practical Implications of the Supreme Court's Mayo and Myriad Decisions on Biotechnology Patent Practices, explores the impact of Supreme Court decisions handed down in 2012 and 2013 that have made it more difficult for companies in the multibillion dollar global life sciences industry to obtain patents.
The report surveys the impact of the Supreme Court decisions Mayo Collaborative Services v. Prometheus Laboratories ("Mayo") and Association for Molecular Pathology v. Myriad Genetics ("Myriad") – and the U.S. Patent and Trademark Office's (PTO) interpretation of those decisions – on companies that own or license patents across the life sciences industry. The authors interviewed 24 industry legal professionals representing the biotechnology industries, including corporate representatives affected by the changes and patent attorneys who deal regularly with the PTO, and gathered commentary from PTO officials. The study also analyzed approximately 350 patent applications recently rejected by the PTO that have been impacted by these decisions.
The report notes that recent interpretations of the law have "shaken the life sciences industry at its roots." Interviews with industry experts find that some of the affected companies believe the current environment "could force inventors and investors to abandon what could be life-saving projects or move to other countries where the laws facilitate innovation." The industry experts noted that the recent Supreme Court decisions, and the PTO's guidance on them, "have rewritten the playbook for biotechnology companies . . . [and] not only limit the scope of what discoveries remain patent eligible, they also transform the way the PTO's patent examiners will review life sciences applications."
"The decisions made by the Supreme Court and the resulting PTO guidance have far-reaching implications for the life sciences industry," said Randy Kubetin, managing editor of Bloomberg BNA's Life Sciences Law & Industry Report. "The industry is still reverberating from the impact of these events and this report offers one-of-a-kind insight and analysis that makes it of great benefit to the entire life sciences industry."
"This study demonstrates that several recent Supreme Court decisions are increasingly impacting areas of biotechnology," said Hans Sauer, Deputy General Counsel for Intellectual Property, BIO. "The United States Patent and Trademark Office's interpretation of case law has led to the rejection of patent applications on industrial or medicinal biotech products."
"We were surprised to see how many claims the Patent and Trademark Office rejected on the basis of the Supreme Court's recent decisions," said Matthew McFarlane, co-author and Principal with the law firm Robins, Kaplan, Miller & Ciresi L.L.P. "It's important for inventors large and small to appreciate the wide variety of life sciences patent applications affected by relatively recent reinterpretations of the law."
Tara Sharp, an associate with Robins Kaplan and co-author of the report, noted that, "The range of inventions impacted by the Supreme Court decisions and PTO guidelines is vast, and covers diverse technologies such as methods for diagnosing disease, biological products, including antibodies and proteins, and even plants and metallic compounds."
An executive summary of the report is available at www.bna.com/BIO_2014_PR.
About Bloomberg BNA
Bloomberg BNA, a wholly owned subsidiary of Bloomberg, is a leading source of legal, regulatory, and business information for professionals. Its network of more than 2,500 reporters, correspondents, and leading practitioners delivers expert analysis, news, practice tools, and guidance — the information that matters most to professionals. Bloomberg BNA's authoritative coverage spans a full range of legal practice areas, including tax & accounting, labor & employment, intellectual property, banking & securities, employee benefits, health care, privacy & data security, human resources, and environment, health & safety.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter. Subscribe to the BIO Newsletter.
About Robins, Kaplan, Miller & Ciresi L.L.P.
Robins, Kaplan, Miller & Ciresi L.L.P. (http://www.rkmc.com) is a litigation firm whose clients include numerous Fortune 500 corporations, emerging markets companies, entrepreneurs, and individuals as both plaintiffs and defendants. With more than 220 lawyers located in Atlanta, Boston, Los Angeles, Minneapolis, New York and Naples (FL), the firm is frequently engaged in high-stakes, complex litigation with significant bottom-line implications for clients. Its business lawyers handle complex transactions in a variety of market segments and industries. Chambers USA 2014 ranked the firm in the first band nationally in the Antitrust: Plaintiffcategory, and regularly gives it top rankings for litigation. Corporate Counsel has named the firm a "Go-To Law Firm" and Multicultural Law has ranked the firm as one of the top national law firms for diversity. The American Lawyer ranked the firm seventh in the country in the 2013 Pro Bono Survey, and twice named the firm to the A-List.
SOURCE Bloomberg BNA